HBB gene

HBB gene
Name	HBB
Locus	11p15.4
Chromosomal location	Chromosome 11 (human chromosome)
Aliases	beta-globin, hemoglobin subunit beta gene
Products	Beta globin protein
OMIM	141900

HBB gene The HBB gene encodes the beta subunit of hemoglobin and sits on Chromosome 11 (human chromosome) within a cluster notable in molecular genetics, population genetics, paleogenomics, and clinical medicine. Research on HBB has intersected with studies by institutions like Harvard University, University of Cambridge, Massachusetts Institute of Technology, Stanford University, and global projects such as the Human Genome Project and the 1000 Genomes Project. Investigations span evolutionary history involving populations in Sub-Saharan Africa, Mediterranean Sea regions, and the Indian subcontinent and intersect with public health agencies like the World Health Organization, Centers for Disease Control and Prevention, and the National Institutes of Health.

Gene and genomic context

The HBB locus is located at 11p15.4 near developmental and regulatory regions studied by groups at Cold Spring Harbor Laboratory, Sanger Institute, and Broad Institute. In genomic maps generated by the ENCODE Project Consortium and datasets deposited by European Bioinformatics Institute, the HBB cluster is adjacent to HBD, HBE1, HBG1, and HBG2 and is embedded within chromatin contexts analyzed in projects led by UCSC Genome Browser, GENCODE Consortium, and International HapMap Project. Comparative genomics work comparing Neanderthal genome and Denisovan genome sequences has explored HBB-area polymorphisms, and linkage disequilibrium patterns have been characterized in cohorts from institutions such as Wellcome Trust and national biobanks including UK Biobank.

Protein structure and function

The beta-globin peptide combines with alpha-globin to form tetrameric hemoglobin, a focus of structural biology groups at European Molecular Biology Laboratory and crystallographers awarded by the Nobel Prize for macromolecular structure studies. High-resolution structures deposited by the Protein Data Bank and analyzed in papers from Max Planck Society demonstrate interactions critical for oxygen binding and allosteric regulation alongside molecules studied in physiology by Johns Hopkins University and Mayo Clinic. Functional assays from laboratories at University of Oxford and University of California, San Francisco show how beta-globin variants alter heme coordination, cooperativity, and interactions with metabolites characterized historically by researchers at Rockefeller University and Columbia University.

Expression and regulation

HBB expression is developmentally regulated, switching during gestation and infancy in patterns documented by the Howard Hughes Medical Institute and developmental biology groups at University College London. Regulatory control involves promoters, locus control regions, and transcription factors studied in landmark work from Cold Spring Harbor Laboratory and the Max Planck Institute for Molecular Genetics, including factors noted in clinical genetics at Mayo Clinic and Cleveland Clinic. Epigenetic modifications profiled in consortia like Roadmap Epigenomics Project and chromatin looping observed by teams at MIT and University of Chicago coordinate HBB expression in erythroid lineage cells characterized in hematology centers such as Fred Hutchinson Cancer Center.

Clinical significance and associated disorders

Variants in HBB underlie major hemoglobinopathies that are central to clinical programs at World Health Organization, American Society of Hematology, Royal College of Physicians, and specialty centers at St. Jude Children's Research Hospital and Great Ormond Street Hospital. Conditions associated include sickle cell disease and β-thalassemia, which have driven public health initiatives in regions governed by bodies such as Pan American Health Organization and national ministries like Ministry of Health (India). Clinical trials registered with agencies like the Food and Drug Administration and European Medicines Agency evaluate therapies developed by biotech firms and academic spinouts affiliated with University of Pennsylvania and Boston Children's Hospital. Epidemiological patterns have been traced in studies involving World Bank health programs and nations with historical malaria selection such as Nigeria, Greece, Italy, and India.

Genetic variants and mutation mechanisms

Pathogenic HBB variants include point mutations, insertions, deletions, and regulatory defects characterized in mutation databases curated by Human Gene Mutation Database and clinical registries maintained by ClinVar. Mechanistic studies by molecular genetics groups at Yale University and University of Toronto document missense changes like the canonical mutation studied originally by researchers at University of Minnesota, splice-site defects, promoter mutations, and gene conversion events involving paralogs noted in evolutionary studies from Smithsonian Institution and American Museum of Natural History. Natural selection signals linked to malaria resistance were explored in landmark population studies involving Pasteur Institute and field work coordinated by Bill & Melinda Gates Foundation.

Diagnostic testing and therapeutic approaches

Diagnostic modalities include hemoglobin electrophoresis, high-performance liquid chromatography developed in instrumentation labs at Siemens Healthineers and Roche Diagnostics, molecular sequencing pipelines from Illumina and Oxford Nanopore Technologies, and newborn screening programs implemented by health systems in collaboration with UNICEF and CDC. Therapeutics range from hydroxyurea protocols refined at King's College London and hematopoietic stem cell transplantation programs at Fred Hutchinson Cancer Center to gene therapy and genome editing trials conducted by teams at Boston Children’s Hospital, Sangamo Therapeutics, and university spinouts linked to University of California, Berkeley and University of Pennsylvania. Policy, ethics, and access discussions involve stakeholders like National Human Genome Research Institute, World Health Organization, and advocacy groups such as Sickle Cell Disease Association of America.

Category:Genes on human chromosome 11